OGN vs PFE
OGN: A diversified pharmaceutical company spun from Merck focusing on established branded medicines and medical devices for women's health, infectious disease, and other therapeutic areas. PFE: Global biopharmaceutical company discovering, developing, and manufacturing prescription medicines and vaccines across oncology, immunology, cardiovascular, and infectious disease.
Side-by-side fundamentals
| Metric | OGN | PFE | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $13.52 | $24.82 | |
| Market cap as of 2026-07-23 | $3.6B | $142.0B | |
| P/E as of 2026-07-23 | 14.43 | 18.96 | OGN lower |
| PEG as of 2026-07-23 | 2.14 | -3.38 | PFE lower |
| Net margin as of 2026-07-23 | +4.0% | +11.8% | PFE higher |
| Gross margin as of 2026-07-23 | +52.8% | +74.8% | PFE higher |
| Operating margin as of 2026-07-23 | +8.7% | +15.4% | PFE higher |
| ROE as of 2026-07-23 | +29.9% | +8.4% | OGN higher |
| ROA as of 2026-07-23 | +1.9% | +3.6% | PFE higher |
| Debt / equity as of 2026-07-23 | 9.49 | 0.72 | PFE lower |
| Revenue growth (YoY) as of 2026-07-23 | -2.1% | +1.4% | PFE higher |
| Revenue CAGR (3y) SEC XBRL | +0.2% | -14.8% | OGN higher |
| Dividend yield as of 2026-07-23 | +0.6% | +6.9% | PFE higher |
| Dividend streak (yrs) SEC XBRL | 1 | 5 | PFE higher |
| Beta as of 2026-07-23 | 1.52 | 0.28 | |
| 1-year return as of 2026-07-22 close | +37.7% | -1.3% | OGN higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.